Successful treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate: A case series
M Arboleda, S Barrantes, LY Úsuga… - Revista da Sociedade …, 2019 - SciELO Brasil
Cutaneous leishmaniasis (CL) is a high-morbidity, vector-borne disease endemic to
Colombia. Unlike conventional systemic antileishmanial therapy, intralesional meglumine …
Colombia. Unlike conventional systemic antileishmanial therapy, intralesional meglumine …
Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis
MCO Duque, ÉCFE Vasconcellos… - Revista da Sociedade …, 2016 - SciELO Brasil
INTRODUCTION: Intralesional treatment for cutaneous leishmaniasis has been applied for
over 30 years at the Oswaldo Cruz Foundation, Rio de Janeiro, with good therapeutic results …
over 30 years at the Oswaldo Cruz Foundation, Rio de Janeiro, with good therapeutic results …
[HTML][HTML] Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre
RE Silva, A Toledo Júnior, MC Senna… - Memórias do Instituto …, 2016 - SciELO Brasil
Although intralesional meglumine antimoniate (MA) infiltration is considered an option for
cutaneous leishmaniasis (CL) therapy and is widely used in the Old World, there have been …
cutaneous leishmaniasis (CL) therapy and is widely used in the Old World, there have been …
Comparison between systemic and intralesional meglumine antimoniate therapy in a primary health care unit
MC de Oliveira Duque, JJQ Silva, PAO Soares… - Acta tropica, 2019 - Elsevier
Cutaneous leishmaniasis (CL) is not a life-threatening condition. However, its treatment can
cause serious adverse effects and may sometimes lead to death. Recently, safer local …
cause serious adverse effects and may sometimes lead to death. Recently, safer local …
[HTML][HTML] Intralesional meglumine antimoniate for treatment of cutaneous leishmaniasis patients with contraindication to systemic therapy from Rio de Janeiro (2000 to …
ECF e Vasconcellos, MIF Pimentel… - The American journal …, 2012 - ncbi.nlm.nih.gov
We evaluated the effectiveness and safety of intralesional meglumine antimoniate (MA) in
24 not submitted to previous treatment patients with cutaneous leishmaniasis (CL) and with …
24 not submitted to previous treatment patients with cutaneous leishmaniasis (CL) and with …
Meglumine antimoniate intralesional infiltration for localised cutaneous leishmaniasis: a single arm, open label, phase II clinical trial
DB Ramalho, RE Silva, MCR Senna… - Memórias do Instituto …, 2018 - SciELO Brasil
BACKGROUND Cutaneous leishmaniasis (CL) is a world-wide health problem which
currently lacks effective, affordable and easy to use therapy. Recently, the meglumine …
currently lacks effective, affordable and easy to use therapy. Recently, the meglumine …
[HTML][HTML] Intralesional treatment with meglumine antimoniate in three patients with New World cutaneous leishmaniasis and large periarticular lesions with …
MIF Pimentel, ÉCF Vasconcellos, CO Ribeiro… - Revista da Sociedade …, 2017 - SciELO Brasil
Abstract Although New World cutaneous leishmaniasis is not itself a life-threatening
disease, its treatment with systemic antimonials can cause toxicity that can be dangerous to …
disease, its treatment with systemic antimonials can cause toxicity that can be dangerous to …
An old drug and different ways to treat cutaneous leishmaniasis: intralesional and intramuscular meglumine antimoniate in a reference center, Rio de Janeiro, Brazil
C Oliveira-Ribeiro, MIF Pimentel… - PLoS Neglected …, 2021 - journals.plos.org
Background Treatment of cutaneous leishmaniasis (CL) remains challenging since the
drugs currently used are quite toxic, thus contributing to lethality unrelated to the disease …
drugs currently used are quite toxic, thus contributing to lethality unrelated to the disease …
A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania …
LO Neves, AC Talhari, EPN Gadelha… - Anais brasileiros de …, 2011 - SciELO Brasil
Fundamentals: American tegumentary leishmaniasis (ATL) treatment remains a challenge,
since most available drugs are injectable and only a small number of comparative …
since most available drugs are injectable and only a small number of comparative …
[PDF][PDF] Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L.(V.) guyanensis in Brazil: therapeutic response to meglumine …
GA Romero, MV Guerra, MG Paes… - The American journal of …, 2001 - academia.edu
We conducted a quasi-experimental study to compare the response to meglumine
antimoniate in patients with localized cutaneous leishmaniasis from two endemic areas of …
antimoniate in patients with localized cutaneous leishmaniasis from two endemic areas of …
相关搜索
- meglumine antimoniate cutaneous leishmaniasis
- meglumine antimoniate rio de janeiro
- meglumine antimoniate intralesional treatment
- successful treatment cutaneous leishmaniasis
- meglumine antimoniate systemic therapy
- meglumine antimoniate old drug
- meglumine antimoniate therapeutic response
- old drug cutaneous leishmaniasis
- therapeutic response cutaneous leishmaniasis
- rio de janeiro cutaneous leishmaniasis
- meglumine antimoniate leishmaniasis patients
- meglumine antimoniate leishmania guyanensis
- leishmania guyanensis cutaneous leishmaniasis